Clinical Trial Update: Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of simtuzumab in adults with advanced liver fibrosis due to NASH; study terminated with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis Due to Nonalcoholic Steatohepatitis

Drugs mentioned

• Simtuzumab (simtuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Liver Fibrosis Due to NASH | Phase 2 | Status: TERMINATED | Results posted: 2019-03-27